I don't disagree with you at all Max. My point is not really so...

First 32 Last

Share
Profile

Follow
Hoyland

4,015 Posts.

127

12/08/15

15:15

Post #: 15794375
Share

Originally posted by Maxineamillion ↑

Hi Hoyland, thanks for your response. However, there are plenty of companies out there carrying on after their one and only drug in the clinic has failed. 240 million people chronically infected with HBV without any good treatment options suggest that efficacy in PI/IIa would certainly be pretty good incentive for a colloboration or takeover regardless of how well TT-034 has done. Different disease and, if the AAV-8 doesn't penetrate the HCVs negative strand, it doesn't necessary mean it won't work for HBV. Personally, I just don't know enough about the science to make assumptions, but, I'm pretty sure that David Suhy and Mick Graham would be looking at this very closely before pumping millions into it's development and paying millions to Biomics to get 50% back.

I also think that the AMD program has very good prospects, and I just don't think that extrapolating results from TT-034 that uses a different vector is that worthwhile.

Expand

I don't disagree with you at all Max. My point is not really so much about the technology, it is about the credibility of the management team and how their capacity to deliver on any pipeline program will be viewed by the market. I am sure we still have enough to offer to keep the company viable even if TT-034 is less than spectacular, but not without changing some of the current team.

BLT Price at posting: 77.0¢ Sentiment: None Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

SVL

Silver Mines models five new calderas close to 396Moz Bowdens deposit

LU7

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Microcap Wrap: 5 explorers with news out today

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

SS1

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

AVA

Ava Risk Group expands US presence with A$0.7M Substation Deal

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

RCE

Recce's R327 found effective against E.coli during clinical trial

CMX

ChemX Materials kicks off first stage works at WA high purity alumina pilot

LRV

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

There are more pages in this discussion • 18 more messages in this thread...

First 32 Last

Add BLT (ASX) to my watchlist

I don't disagree with you at all Max. My point is not really so...

Top Stories

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Microcap Wrap: 5 explorers with news out today

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Ava Risk Group expands US presence with A$0.7M Substation Deal

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Recce's R327 found effective against E.coli during clinical trial

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Featured News